Cognitive Assessment Tools for Huntington's Disease.
ConditionHuntington Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30-65
SponsorOhio State University
About this trial
The purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in Huntington Disease (HD) clinical trials that might be useful both for initial screening and for clinical trial application. One is the Coding Test and the other is the Self-Administered Gerocognitive Examination (SAGE). Both the Coding Test and the SAGE have been used for assessments of individuals with other neurodegenerative diseases, including Alzheimer's Disease, Parkinson's Disease and Lewy Body Disease, but data is lacking on their use in individuals with HD.
Eligibility criteria
Qualifiers
Males and females aged 30-65 (inclusive) at the time of signing the informed consent form.
Genetic diagnosis of HD as defined by a CAG repeat size ≥ 40.
A clinical diagnosis of HD as defined by a Diagnostic Confidence Level (DCL) of 4.
Vision and hearing sufficient for compliance with tests.
Disqualifiers
Age of symptom onset less than 19 years old or greater than 60 years old.
Any serious neurological disorder aside from HD, including but not limited to Alzheimer's disease, Parkinson's disease, Frontotemporal dementia, Lewy body dementia, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury… etc. that in the opinion of the investigator is clinically significant.
Any ongoing serious medical condition that in the opinion of the investigator is clinically significant. This includes autoimmune diseases, ongoing treatment for cancer, congestive heart failure, severe pulmonary disease, or any history of a seizure disorder (including the need to take anti-epileptics to prevent seizure).
Subjects who are pregnant or breast feeding
Trial design
Treatments tested in this trial
- Assessments
Treatment groups
76 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov